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ABSTRACT 
Chronic renal failure (CRF) impedes renal excretion of drugs, and their metabolism by reducing 
the expression of liver cytochrome P450 (CYP450). Uremic serum contains factors, such as 
parathyroid hormone (PTH), that decrease liver CYP450s. CYP450s are also involved in the 
metabolism of xenobiotics in the brain. This study investigates (1) the effects of CRF on rat brain 
CYP450, (2) the role of PTH in the downregulation of brain CYP450s in CRF rats, and (3) the 
effects of PTH on CYP450s in astrocytes. Protein and mRNA expression of CYP450s were 
assessed in the brain of CRF and control rats as well as from control or CRF rats that underwent 
parathyroidectomy (PTX) one week prior to nephrectomy. CYP3A activity was measured using 
3-[(3, 4-difluorobenzyl) oxy]-5, 5-dimethyl-4-[4-methylsulfonyl) phenyl] furan-2(5H)-one 
metabolism in brain microsomal preparation. CYP3A protein expression was assessed in primary 
cultured astrocytes incubated with serum obtained from CRF or control rats, or with PTH. 
Significant downregulations (≥40%) of CYP1A, CYP2C11 and CYP3A proteins were observed 
in microsomes from CRF rat brains. CYP3A activity reduction was also observed. CYP3A 
expression and activity were unaffected in PTX- pre-treated CRF rats. Serum of PTX-treated 
CRF rats had no impact on CYP3A levels in astrocytes compared to that of untreated CRF rats. 
Finally, PTH addition to normal calf serum induced a reduction in CYP3A protein similar to CRF 
serum suggesting that CRF induced hyperparathyroidism is associated with a significant decrease 
in CYP450 drug-metabolizing enzymes in the brain, which may have implications in drug 
response.
DMD # 70052 
5
INTRODUCTION
Cytochrome P450 (CYP450) proteins are the major catalyst of phase I metabolism. They 
are involved in the oxidative metabolism of endogenous and exogenous substrates such as 
xenobiotics, cholesterol, steroids and vitamin D metabolism. CYP450 expression is highest in the 
liver, but can also be found in various organs including the intestine, the kidneys, the lungs and the 
brain.  
Brain CYP450s are involved in the metabolism of xenobiotics, such as antidepressants, 
opiates, steroids and antipsychotics, as well as endobiotics, such as steroids, arachidonic acid, 
dopamine and serotonin (Miksys and Tyndale, 2013). CYP450 isoforms such as CYP1A1/2, 
CYP2B1, CYP2C11, CYP2D1-6, CYP2E1, CYP3A1 and CYP4F have been identified in rat brain 
(Morse et al., 1998; Imaoka et al., 2005; Yadav et al., 2006; Miksys and Tyndale, 2013). Although 
the overall expression of individual CYP450 in the brain is very low, very high activity of specific 
CYP450 enzymes can be found in different brain regions such as the hippocampus, the cerebellum, 
cortex and hypothalamus, where these proteins are suggested to participate in local endobiotic and 
xenobiotic metabolism (Miksys and Tyndale, 2002; Yadav et al., 2006; Meyer et al., 2007).  
Over the past 15 years, many studies have demonstrated that chronic renal failure (CRF) 
significantly affects the expression and activity of liver, intestine and kidney CYP450, thus altering 
extra-renal drug metabolism (Leblond et al., 2000; Leblond et al., 2001; Leblond et al., 2002; Naud 
et al., 2011; Naud et al., 2012b) and vitamin D metabolism (Michaud et al., 2010). Parathyroid 
hormone (PTH) has been identified as a major factor responsible for the CYP450 downregulation in 
CRF rats (Michaud et al., 2006; Michaud et al., 2010). In light of these studies, we hypothesized 
that CRF could also impede brain CYP450 expression and/or activity, and that PTH could be 
involved in brain CYP450 modulation.  
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The objective of this study was thus to investigate the effect of CRF on CYP450s in whole 
or specific regions of rat brain, and the involvement of PTH in it. To address this, we have 
measured the protein and mRNA expression of CYP450s in cerebellum, cortex, hippocampus and 
remaining brain tissue from CRF and CTL rats. To assess the involvement of PTH, we measured 
the protein expression and the activity of CYP3A in microsomes purified from brains of CRF, 
parathyroidectomized-CRF (CRF-PTX), parathyroidectomized-control (CTL-PTX) and control rats. 
To investigate further the role of PTH, we measured the expression levels of CYP3A in primary rat 
astrocytes cultured in the presence of sera obtained from CTL, CRF, CRF-PTX and CTL-PTX rats. 
Finally, astrocytes were incubated with high concentration PTH, to evaluate the effect of PTH on 
CYP3A expression.  
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MATERIALS AND METHODS 
Experimental model 
Male Sprague-Dawley rats (Charles River, Portage, MI), weighing 176 to 225 g were 
housed in the Research Center animal care facility and maintained on Harlan Teklad rodent diet 
(Harlan Teklad Global Diets, Montreal, Canada) and water ad libitum. Animals were allowed an 
acclimatization period of at least 7 days before the first nephrectomy was performed. All the 
experiments were conducted according to the Canadian Council on Animal Care guidelines for care 
and use of laboratory animals and under the supervision of our local animal care committee. 
Chronic renal failure was induced by two-stage 5/6 nephrectomy as described previously 
(Leblond et al., 2001). Rats from control group also underwent two sham laparotomies (day 1 and 
8). Every animal had ad libitum access to water, but in order to limit the effects of CRF-induced 
malnutrition, control pair-fed rats were fed the same amount of chow that CRF rats ate on the 
previous day. At day 41 after the nephrectomy, the rats were housed in metabolic cages and urine 
was collected for 24 hours to determine the clearance of creatinine. Rats were sacrificed by 
decapitation at 42 days for brain and blood collection. Brain was immediately excised, rinsed in ice-
cold saline then either dissected fractions (cerebellum, cortex, hippocampus and remaining brain 
parenchyma, n=12 CTL and 13 CRF) or whole brain (n=13 CTL, 8 CTL-PTX, 13 CRF, 11 CRF-
PTX) were flash-frozen in liquid nitrogen. Samples were stored at -80°C until microsome 
preparation or mRNA extraction. After collection, blood was rapidly stored on ice. After 
coagulation, serum was recovered by centrifugation (600 g for 10 min at 4°C) and samples were 
kept for the measurement of serum creatinine, urea and PTH, and for bioassays with cultured rat 
astrocytes. The remaining sera were stored at -80°C. 
Total parathyroidectomy (PTX) was performed as previously described (Klin et al., 1996; 
Michaud et al., 2006; Michaud et al., 2010). Briefly, surgical PTX was carried out under a surgical 
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microscope, without removal of the thyroid tissue. The success of the PTX was ascertained by a 
significant decrease of calcium after PTX. To avoid hypocalcemia, PTX animals were then 
supplemented with calcium by adding calcium gluconate to drinking water (control 5%; CRF 
2.5%). Rats were then allowed to recover for a week before 5/6 nephrectomy. Control rats received 
sham surgery in the neck region. 
Preparation of brain microsomes 
Microsomes from cerebellum, cortex, hippocampus and remaining brain parenchyma or 
from whole brain were isolated as published by Cinti (Cinti et al., 1972; Leblond et al., 2000). 
The resulting pellet was suspended in either phosphate buffered saline containing 0.1 mM PMSF 
for Western blot analysis or in sucrose 0.25 M for CYP3A activity assessment. Samples were then 
sonicated on ice for 10 seconds to ensure homogeneity. Protein concentration was determined using 
the method of Lowry (Lowry et al., 1951), using bovine serum albumin as a reference protein. 
Aliquots were stored at -80°C up to Western blot analysis or CYP3A activity assessment. 
Western blot analysis 
Brain CYP450s levels were assessed by Western blot analysis following a previously 
described protocol (Leblond et al., 2002; Naud et al., 2007; Naud et al., 2008; Naud et al., 2011). 
Briefly, proteins were separated on 9% SDS-PAGE and transferred to nitrocellulose membrane. 
Non-specific proteins were blocked by incubating Western blot membranes in 5% skim milk in 
PBS. CYP450 proteins were detected using specific antibodies. CYP1A1/2 and CYP2E1 
antibodies were from US Biologicals (Salem, MA), and CYP2C11, CYP2D and CYP3A 
antibodies were from Abcam (Cambridge, MA), Creative Biomart (Shirley, NY) and Millipore 
(Billerica, MA), respectively. Beta-Actin, used as a loading control, was detected using a mouse 
anti-chicken β-Actin (Neo-Markers, Fremont, CA). Secondary antibodies against mouse or rabbit 
IgG were from Sigma (St-Louis, MO). Antibodies were diluted in 0.5% skim milk and 
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membranes were washed with 0.1% Tween 20 in phosphate buffered saline. All blots were 
revealed using Lumi-light chemiluminescent reagents (Roche Diagnostics, Laval, Quebec, 
Canada). Each membrane was probed sequentially for a specific CYP isoform then for β-Actin.  
Individual CYP450 protein levels were quantified by measuring the density of bands 
using an ImageQuant™ LAS 4000 software (GE Healthcare, Mississauga, Ontario, Canada). The 
measured density value was reported as a ratio over the expression of β-actin band intensity. 
Comparison of control and CRF group was always performed on the same membrane. The mean 
CYP/β-Actin ratio for the control group was arbitrarily defined as 100% and all samples were 
expressed as a percentage of this value. Each blot was repeated in two independent experiments.  
mRNA analysis 
Total RNA was extracted from frozen tissue using Trizol reagent (Invitrogen, Burlington, 
Ontario, Canada) according to the manufacturer’s protocol. RNA concentration was determined 
by measuring absorbance at a wavelength of 260 nm. One µg of total RNA was used to prepare 
cDNA by reverse transcription using SuperScript® VILO™ cDNA Synthesis Kit from 
Invitrogen. Gene expressions were measured using appropriate TaqMan gene expression assays 
from Applied Biosystems (Carlsbad, CA). Table 1 shows the TaqMan gene expression assays 
used for the quantification of mRNA for each enzyme. Gene expression was determined using the 
ΔΔCT method (Livak and Schmittgen, 2001) using β-actin expression as a reference. 
Evaluation of CYP3A activity 
In order to evaluate the metabolic activity of CYP3A in 200 µg of microsomes prepared 
from whole brain extract of CTL, CTL-PTX, CRF and CRF-PTX rats, a selective fluorescent 
probe, 3-[(3,4-difluorobenzyl)oxy]-5,5-dimethyl-4-[4-methylsulfonyl)phenyl]furan-2(5H)-one 
(DFB) that is specifically metabolized by rat CYP3A to 3-hydroxy-5, 5-dimethyl-4-[4-
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(methylsulfonyl) phenyl] furan-2(5H)-one (DFH) was used as previously reported (Nicoll-
Griffith et al., 2004; Michaud et al., 2007; Michaud et al., 2008). DFH fluorescence was 
determined on a cytofluorometer (Cytofluor 4000/TR, Perspective Biosystems, Framingham, MA) 
using appropriate wavelength (excitation filter: 360/40 nm; emission filter: 460/40 nm). The 
standard curve was prepared with known dilutions of DFH.  
Isolation and culture of rat astrocytes 
To assess the impact of uremic serum or PTH on the ex-vivo expression of CYP450 in 
brain, we incubated rat astrocytes with serum from nephrectomized and PTX rats or with PTH 
and evaluated CYP3A protein expression. Rat astrocytes were isolated and cultured as previously 
described from unknown gender newborn rat pups (Booher and Sensenbrenner, 1972; Perriere et 
al., 2005; Naud et al., 2012a). When cells reached confluence, the standard culture medium was 
replaced with culture medium containing 10% serum from CTL, CTL-PTX, CRF or CRF-PTX 
rats (1 serum/flask) or medium containing 10% calf serum supplemented with 10 nM rat PTH 
(Rat synthetic 1-34 PTH, Sigma) or not. After 48 h of culture, cells were trypsinized, pelleted and 
homogenized in phosphate buffered saline containing 0.1 mM PMSF. Protein concentrations were 
determined using the Micro BCA Protein Assay Kit from Thermo Fisher Scientific (Rockford, 
IL). One hundred  g of protein lysate was used for Western Blot analysis of CYP3A. 
Other assays 
Blood and urine chemistries were determined with an Architect C1600 clinical analyzer 
(Abbott, Saint-Laurent, QC, Canada). PTH serum levels were measured using the Rat intact PTH 
ELISA Kit (Alpco Diagnostics, Salem, NH), which measures intact 1-84 PTH. The lowest 
detectable level was 29 pg/ml. 
Statistical analysis 
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 Results are expressed as mean ± SD. Statistical analysis was performed using SPSS 
software. Differences between groups were assessed using an unpaired Student’s t test or an 
ANOVA test. Significant ANOVA was followed by a Scheffe post hoc comparison of groups. 
The threshold of significance was p<0.05.  
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RESULTS
Biochemical parameters in control and CRF rats 
 Table 2 presents the biochemical parameters and body weight of control and CRF rats. As 
shown in the table, compared to control animals, CRF rats had higher levels of serum creatinine 
and urea, and lower creatinine clearance (reduced by 75%, p < 0.001). Also, compared to CTL 
animals, CRF rats had 10-fold higher levels of PTH (p < 0.05). There was no difference in body 
weight between control and CRF rats. 
CYP450 expression in the dissected brain of control and CRF rats 
First, we tested in control and CRF rats whether CRF could modify the brain CYP450 
expression. Figure 1 shows the protein expression levels of various CYP450s in cerebellum, 
cortex, hippocampus and remaining brain tissue of control and CRF rats. Western blot analysis 
showed a 25 to 50% (p < 0.05) decrease in CYP1A, CYP2C11 and CYP3A protein levels in brain 
microsomes of CRF rats compared to control group, whereas CYP2D4 and CYP2E1 expression 
was found similar in both groups. Subdivision of the brain in 4 parts (cerebellum, cortex, 
hippocampus and remaining of the brain) showed that the effect of CRF on the expression of a 
specific CYP450 isoform was evenly distributed across the entire organ. Since we found no 
difference between various parts of the brain, the whole organ was used for subsequent analysis 
of the effects of PTH on CYP3A expression and activity. When we assessed the mRNA levels of 
individual CYP450 isoform in the brain of CRF rats, we did not find any significant modulation 
between groups (Supplemental Figure 1). 
CYP3A protein expression in whole brain microsomes of CRF and parathyroidectomized 
CRF rats
To evaluate the role of PTH in the in vivo modulation of CYP3A, we surgically removed 
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the parathyroid glands 7 days prior to the first nephrectomy, thus preventing secondary 
hyperparathyroidism. Table 3 presents the body weight and biochemical characteristics of 
parathyroidectomized rats. Compared to control animals, CRF rats had significantly higher levels 
of PTH (p < 0.05), while in PTX animals PTH levels were below the lowest detectable 
concentration and were unaffected by CRF.  
CYP3A protein expression was measured in whole brain microsomes purified from CTL, 
CRF, CTL-PTX and CRF-PTX rats. As shown in Figure 2 there was a significant decrease of 
CYP3A protein expression in whole brain microsomes isolated from CRF rats compared to CTL, 
and PTX treatment prevented the CYP3A protein level reduction in CRF rats suggesting that PTX 
prevents the CYP3A downregulation induced by CRF. No significant modulation of mRNA 
expression was observed in all groups (Supplemental Figure 2). 
CYP3A activity in whole brain microsomes of CRF rats 
To evaluate if CRF affected CYP3A activity as well, we assessed in vitro, using 
fluorescently labeled DFB, the enzymatic activity of CYP3A. DFB is converted into DFH by 
CYP3A and fluorescence intensity of DFH is readily measured on a cytofluorometer. To this end, 
we measured the conversion of DFB into DFH by CYP3A in brain microsomes isolated from 
CTL, CRF, CRF-PTX, and CTL-PTX rats. As shown in Figure 3, brain microsomes purified from 
rats with CRF produced 50% less DFH (p < 0.05) compared to CTL, CTL-PTX and CRF-PTX 
rats, suggesting a decrease in CYP3A activity by CRF is likely due to impact of parathyroid-
derived factor such as PTH. 
CYP3A expression in astrocytes cultured with serum from CTL, CRF and PTX rats 
To confirm the possible role of PTH present in uremic serum of CRF rats in the in vivo
downregulation of brain CYP3A, we evaluated the effects of serum from control and CRF rats on 
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cultured astrocytes isolated from normal rats. We incubated normal rat astrocytes for 48 h with 
serum from control, CTL-PTX, CRF or CRF-PTX animals. As shown in Figure 4, serum from 
CRF rats reduced CYP3A expression by 30% (p < 0.05), whereas serum from CRF-PTX rats had 
no effects on CYP3A levels in rat astrocytes.  
CYP3A expression in astrocytes cultured with PTH 
To provide direct evidence for role of PTH in modulating CYP3A levels in astrocytes, we 
cultured astrocytes isolated from normal rats in the presence of purified PTH. Results depicted in 
Figure 5 show that incubation of astrocytes with 10 nM PTH decreased CYP3A by 30% 
(p < 0.05) compared to control astrocyte culture lacking PTH, suggesting that CRF in rats may 
result in high serum PTH and that this could be an important factor in the downregulation of brain 
CYP3A in CRF rats. 
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DISCUSSION 
Brain cytochrome P450 plays an important role in the local metabolism of endogenous and 
exogenous compounds. Alteration in brain cytochrome P450 levels could significantly affect 
normal brain function or lead to local toxicity of drugs. It is a well recognized fact that CRF patients 
are subject to elevated drug toxicity and that CYP450 metabolism is impaired. The purpose of this 
study was to investigate the effect of CRF on brain CYP450 in whole brain or specific regions of 
brain of rats and the involvement of PTH. To address this, we measured CYP450 in cerebellum, 
cortex, hippocampus and remaining brain tissue from CRF and CTL rats. To investigate the role of 
PTH, we measured CYP3A in whole brain microsomes derived from CRF, CRF-PTX, CTL-PTX 
and CTL rats. This study demonstrates that CRF affects the expression and activity of specific 
isoforms of brain CYP450s (CYP3A, 2C11 and 1A) and that PTH could be a mediator of this 
modulation. 
Modulation of CYP450 described in this study is similar to that observed in the liver and 
intestine of CRF rats (Leblond et al., 2001; Leblond et al., 2002). Indeed, in the different brain 
regions, we observed downregulations of CYP3A, CYP2C11 and CYP1A protein expression, but 
no modulation of CYP2D4 and CYP2E1 (Figure 1). In rat liver and intestine, endogenous factors 
were shown to be responsible for the CYP450 impairment. Furthermore, in the liver, PTH was 
identified as the major mediator for the CYP3A modulation (Michaud et al., 2006; Michaud et al., 
2010).  
To further develop our hypothesis that CRF may affect CYP450 levels in brain via altered 
PTH levels, we first evaluated CYP3A expression in whole brain microsomes from rats that 
underwent total parathyroidectomy. Whole brain microsomes were used because CYP450 
modulations had proven to be similar in all brain regions (Figure 1), and because using whole brain 
allowed for a higher sample yield. As shown in Table 3, PTX animals had undetectable PTH levels, 
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while CRF animals had significantly increased levels compared to CTL animals. Also, CRF and 
CRF-PTX animals had similar renal impairment as shown by their respective creatinine clearance 
rate. Figure 2 shows that, similarly to that observed in rat liver (Michaud et al., 2006), 
parathyroidectomy abrogated the downregulation of CYP3A protein in whole brain microsomes 
from CRF animals. PTX alone had no impact on CYP3A expression, as shown in the CTL-PTX 
group. In vitro, sera from CRF rats decreased CYP3A in normal rat astrocytes, whereas sera from 
CTL and PTX rats did not (Figure 4). Also, incubation of astrocytes with 10 nM purified PTH for 
48 h led to a significant decrease in the protein expression of CYP3A in normal astrocytes 
(Figure 5) supporting the hypothesis that PTH could be a factor in the downregulation of CYP3A 
protein expression in the rat brain in CRF as was previously shown in the liver (Leblond et al., 
2001; Leblond et al., 2002; Michaud et al., 2006). 
Finally, we showed that not only CYP3A expression but also its enzymatic activity are 
reduced in CRF rats whole brain microsomes (Figure 3). CYP3A enzymatic activity was assessed in 
whole brain microsomes from CRF, CTL, CRF-PTX and CTL-PTX rats by the in vitro conversion 
of DFB to DFH. This method was previously shown to be specific to rat CYP3A (Michaud et al., 
2007). This mimics what was previously observed in the liver (Michaud et al., 2006).  
Our results suggest that PTH may be a mediator in the downregulation of brain CYP450 by 
CRF in vitro and in vivo. There are two PTH receptors expressed in the brain: PTH1R and PTH2R, 
the latter having the highest expression (Goswami et al., 2014). Both receptors, in response to PTH 
binding, can increase cAMP production and [Ca2+]i and this can lead to activation of protein kinase 
A (PKA) and phosphorylation of proteins, including CYP450 (Swarthout et al., 2002; Bisello et al., 
2004). Phosphorylation of CYP450 by PKA leads to a decrease in metabolic activity (Pyerin et al., 
1987; Jansson et al., 1990). It can also lead to a downregulation of CYP450 gene expression (Sidhu 
and Omiecinski, 1995; Galisteo et al., 1999). Thus, there is a possibility that the PTH receptors in 
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the brain are stimulated by the increased systemic PTH levels which may in turn, lead to CYP450 
downregulation in CRF. 
A major difference exists, however, between the previously cited reports in the liver and 
intestine (Leblond et al., 2001; Leblond et al., 2002; Michaud et al., 2006) and our results: we found 
no effect of CRF on mRNA expression for the different CYP450 enzymes. This suggests a different 
pathway for the regulation of liver and brain CYP450 in CRF. While significant progress has been 
made in our understanding of regulation of CYP450 in brain, and different regions of brain, (Meyer 
et al., 2007; Miksys and Tyndale, 2013), our data indicate a possible different mode of CYP450 
regulation in brain compared to liver. Our results point towards post-translational regulation, but the 
exact mechanisms involved remains to be identified. 
This study clearly shows that CRF affects the expression of some CYP450 isoforms in 
brain. These enzymes have endogenous and exogenous local functions. Whether altered CYP450 
levels could lead to local drug toxicity or could affect normal brain metabolism remains to be 
studied.  
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Legend of figures 
Figure 1: Protein expression of various CYP450s in the dissected brain of CRF rats. A. 
Protein bands are expressed in densitometry units. The densitometry units measured for 
CYP450s in control (CTL, n=12) and chronic renal failure (CRF, n=13) rats were standardized 
by dividing them by the value obtained for β-actin. The standardized densitometry units of 
control rats were arbitrarily defined as 100% and are represented by the dotted line. Graphic 
shows the mean expression in CRF rats expressed as percent of controls ± SD in cerebellum, 
cortex, hippocampus and remaining brain tissue. *p<0.05, **p<0.01 compared to control rats. B.
Typical blot pictures are shown for each CYP450 isoform and the corresponding β-actin in each 
part of the brain. 
Figure 2: CYP3A protein expression in whole brain microsomes of CRF-PTX rats. Protein 
bands are expressed in densitometry units. The densitometry units measured for CYP3A in 
control (CTL, n=13), parathyroidectomized controls (CTL-PTX, n=8), chronic renal failure 
(CRF, n=13) and parathyroidectomized CRF (CRF-PTX, n=11) rats were standardized by 
dividing them by the value obtained for β-actin. The mean relative quantity of control rats was 
arbitrarily defined as 100%. Graphic shows the mean expression in rats expressed as percent of 
controls ± SD. *p<0.05 compared to control rats. Typical blot pictures are shown for CYP3A 
and the corresponding β-actin in each group. 
Figure 3: CYP3A activity in whole brain microsomes of CRF rats.
CYP3A activity was measured by using DFB as a substrate and measuring its conversion to DFH 
in control (CTL, n=13), parathyroidectomized controls (CTL-PTX, n=8), parathyroidectomized 
CRF (CRF-PTX, n=11) rats and chronic renal failure (CRF, n=13). The mean relative DFH 
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production in control rats was arbitrarily defined as 100%. Graphic shows the mean DFH 
production in rats expressed as percent of controls ± SD. *p<0.05 compared to control rats. 
Figure 4: CYP3A protein expression in astrocytes incubated with rat serum Protein bands 
are expressed in densitometry units. The densitometry units measured for CYP3A in astrocytes 
incubated for 48 h with serum from control (CTL, n=5), chronic renal failure (CRF, n=5), 
parathyroidectomized controls (CTL-PTX, n=4), and parathyroidectomized CRF (CRF-PTX, 
n=4) rats were standardized by dividing them by the value obtained for β-actin. The standardized 
densitometry units of control condition were arbitrarily defined as 100%. Graphic shows the 
mean expression in rats expressed as percent of controls ± SD. *p<0.05 compared to serum from 
control rats. Typical blot pictures are shown for CYP3A and the corresponding β-actin in each 
group. 
Figure 5: CYP3A protein expression in astrocytes incubated with rat PTH Protein bands are 
expressed in densitometry units. The densitometry units measured for CYP3A in astrocytes 
incubated for 48 h without PTH (No PTH, n=4) and with 10 nM PTH (PTH, n=4) rats were 
standardized by dividing them by the value obtained for β-actin. The standardized densitometry 
units of No PTH were arbitrarily defined as 100%. Graphic shows the mean expression in rats 
expressed as percent of No PTH ± SD. *p<0.05 compared to No PTH. Typical blot pictures are 
shown for CYP3A and the corresponding β-actin in each group. 
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Tables and figures 
Table 1. TaqMan gene expression assays used for Real-time PCR 
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Table 2. Characteristics of control and CRF rats 
Group  CTL CRF 
Rats (n)  12 13 
Body weight g 362.8 ± 25.7 371.5 ± 75.9 
Serum creatinine µmol/L 59.4 ± 3.1 197.9 ± 85.9a
Creatinine clearanceb µl/100g/min 244.0 ± 89.9 65.5 ± 27.3a
PTH (n) pg/ml 121.7 ± 26.3 1526.8 ± 568.9a
a: p<0.05 vs. Control group  
Data are the mean ± SD. Measurements were made at the time of sacrifice. Twenty-four hour 
urinary collection was begun the day before. Blood urea and creatinine, and urine creatinine 
were determined with an Architect C1600 clinical analyzer (Abbott, Saint-Laurent, QC, Canada). 
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